Xilio Therapeutics, Inc. Operating Lease, Liability, Current
Xilio Therapeutics, Inc. (XLO) had Operating Lease, Liability, Current of $1.43 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-12
- 2026-06-30: Operating Lease, Liability, Current $1.43M.
- 2026-03-31: Operating Lease, Liability, Current $1.38M.
- 2025-12-31: Operating Lease, Liability, Current $1.34M.
- 2025-09-30: Operating Lease, Liability, Current $1.30M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $1.43M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $1.38M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $1.34M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $1.30M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $1.26M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $1.23M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.19M 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.15M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.12M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.08M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $1.05M 10-K · filed 2025-03-11 |
| 2023-09-30 | $1.01M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $981.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $949.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $918.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | $888.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $858.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $829.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $801.00K 10-K · filed 2023-03-02 |
| 2021-09-30 | $773.00K 10-Q · filed 2021-12-02 |
| 2020-12-31 | $564.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |